Free Shipping Orders >$250
✓ FREE & Private Global Delivery ›
✓ We Dispatch The Freshest Batch
✓ Discreet Shipping Within 24h Daily
✓ 100% Original Products Guaranteed
✓ Great Customer Service
✓ Competitive prices on all products
✓ Only Secure Card Payment Methods ›
✓ Our genuinely Earned Reputation ›
✓ Buy more - Save more ›

Incepta Pharma

Showing the single result

Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established in the year 1999.

The company has a very big manufacturing facility located at Savar and Dhamrai, 35 and 53 kilometers away respectively from the center of the capital city Dhaka. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid-filled hard gelatin capsules, lyophilized injections, human vaccine, etc. Since its inception, Incepta has been launching new and innovative products in order to fulfill the unmet demand of the medical community. The focus has been to bring more new technologically advanced molecules to this country.

The company specializes in value-added high-technology dosage forms like sustained-release tablets, quick mouth dissolving tablets, effervescent tablets, barrier-coated delayed-release tablets, prefilled syringe products, Insulin and Insulin analog, and biological products, among others. It has established a modern research and development laboratory for the development of new, advanced dosage forms for various drugs and devices like poorly soluble drugs, dry powder inhalers, coated pellets, modified release products, taste-masked preparation, etc.

Incepta has a very competent sales team, which promotes the specialties throughout the country. The company virtually covers every single corner of the rural as well as urban areas of Bangladesh. It has its own large distribution network having 28 depots all over the country. The company has a clear vision to become a leading research-based dosage form manufacturing company with global presence within a short period of time. With this view in mind, the company started to expand its business in overseas markets. Currently Incepta exports to 95 countries around the world. With hundreds of brands registered in different countries and many more in the pipeline, Incepta is gradually expanding its global footprint across all the continents.

The company’s state-of-the-Art R&D lab employs sophisticated and advanced technology to bring newer products through research hitherto unknown in this country.

Such activities will not only benefit the company but also the entire pharmaceutical sector of the country. Within very shortest possible time the company is going to embark on the production of Active Pharmaceutical Ingredients (API). Plans are underway to get into reverse engineering and analog research in order to produce a new API.

Incepta Vaccines Limited, a sister concern of Incepta Pharmaceuticals, has already established a State-of-the-Art Human Vaccine production facility. Incepta Vaccines Ltd has already launched human vaccines in the Bangladesh market in June 2011. Incepta emerged as the first Bangladeshi company to acquire the technology to produce Human Vaccine. The larger production capacity will allow the company to supply its vaccines globally.

On 15th January 2011, Incepta implemented a globally acclaimed ERP software system – SAP. Incepta is the first Bangladeshi company to implement SAP to manage resources throughout the company’s operation. This world-class resource management system will allow the company to become more efficient and effective in its day-to-day operation.

The company is continuously expanding its activities beyond the geographical boundary of Bangladesh. The company is open to collaborating with interested and relevant parties in various countries Incepta will continue to strive to provide high-quality medicine at affordable prices to the people here in Bangladesh and other parts of the globe.